Free tool
Oncology stocks
We cover 50 companies grouped under the Oncology theme. The median market value in the group is $2.18B. Across the group, the median move over the past trading day is −0.53%. 60% of the 50 with a 200-day average trade above it. Price change over the past year runs from −77.0% to +281.7% across the middle 80 percent of the group, with a median of +30.7%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
50 of 319 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return | Next report |
|---|---|---|---|---|---|
| BMY | Bristol-Myers Squibb Company | $138.03B | Large cap | +47.01% | Oct 29, 2026 |
| RVMD | Revolution Medicines, Inc. | $46.18B | Large cap | +466.35% | Nov 4, 2026 |
| ONC | BeOne Medicines AG | $42.58B | Large cap | +25.21% | Nov 5, 2026 |
| BNTX | BioNTech SE | $28.28B | Large cap | +9.27% | Nov 3, 2026 |
| INCY | Incyte Corporation | $25.97B | Large cap | +51.01% | Oct 27, 2026 |
| GMAB | Genmab A/S | $21.42B | Large cap | +36.20% | Nov 5, 2026 |
| EXEL | Exelixis, Inc. | $14.05B | Large cap | +45.68% | Oct 27, 2026 |
| SMMT | Summit Therapeutics Inc. | $11.35B | Large cap | −42.63% | Oct 19, 2026 |
| CGON | CG Oncology, Inc. | $6.95B | Mid cap | +196.15% | Nov 9, 2026 |
| ERAS | Erasca, Inc. | $6.70B | Mid cap | +1112.03% | Nov 11, 2026 |
| LNTH | Lantheus Holdings, Inc. | $6.58B | Mid cap | +77.38% | Nov 5, 2026 |
| COGT | Cogent Biosciences, Inc. | $6.39B | Mid cap | +196.85% | Nov 3, 2026 |
| CELC | Celcuity Inc. | $4.65B | Mid cap | +90.31% | Nov 11, 2026 |
| ELVN | Enliven Therapeutics, Inc. | $4.46B | Mid cap | +194.32% | Nov 11, 2026 |
| TNGX | Tango Therapeutics, Inc. | $4.29B | Mid cap | +269.13% | Nov 4, 2026 |
| RLAY | Relay Therapeutics, Inc. | $4.26B | Mid cap | +445.10% | Nov 5, 2026 |
| IDYA | IDEAYA Biosciences, Inc. | $4.01B | Mid cap | +66.32% | Nov 9, 2026 |
| RCUS | Arcus Biosciences, Inc. | $3.92B | Mid cap | +191.29% | Oct 27, 2026 |
| IMNM | Immunome, Inc. | $3.34B | Mid cap | +188.94% | Nov 5, 2026 |
| ZLAB | Zai Lab Limited | $2.92B | Mid cap | −20.06% | Nov 5, 2026 |
| SLS | SELLAS Life Sciences Group, Inc. | $2.77B | Mid cap | +615.10% | Nov 11, 2026 |
| NRIX | Nurix Therapeutics, Inc. | $2.77B | Mid cap | +179.69% | Oct 8, 2026 |
| NUVB | Nuvation Bio Inc. | $2.44B | Mid cap | +135.93% | Nov 2, 2026 |
| NBTX | Nanobiotix S.A. | $2.26B | Mid cap | +394.99% | Sep 29, 2026 |
| URGN | UroGen Pharma Ltd. | $2.25B | Mid cap | +135.11% | Nov 5, 2026 |
| XNCR | Xencor, Inc. Common Stock | $2.11B | Mid cap | +254.61% | Nov 4, 2026 |
| ZYME | Zymeworks Inc. | $2.10B | Mid cap | +96.28% | Nov 5, 2026 |
| NVCR | NovoCure Limited | $2.08B | Mid cap | +50.21% | Oct 29, 2026 |
| VRCA | Verrica Pharmaceuticals Inc. | $84.35M | Micro cap | −13.25% | Nov 13, 2026 |
| OSTX | OS Therapies Incorporated | $76.68M | Micro cap | −34.00% | Nov 16, 2026 |
| CRDF | Cardiff Oncology, Inc. | $76.56M | Micro cap | −54.65% | Nov 12, 2026 |
| PLRX | Pliant Therapeutics, Inc. | $73.69M | Micro cap | −31.36% | Nov 5, 2026 |
| PMVP | PMV Pharmaceuticals, Inc. | $70.03M | Micro cap | −7.75% | Nov 16, 2026 |
| HRTX | Heron Therapeutics, Inc. | $59.27M | Micro cap | −77.04% | Nov 3, 2026 |
| IMMP | Immutep Limited | $56.00M | Micro cap | −77.11% | Sep 2, 2026 |
| HOWL | Werewolf Therapeutics, Inc. | $48.05M | Micro cap | −25.65% | Oct 30, 2026 |
| KPTI | Karyopharm Therapeutics Inc. Common Stock | $44.46M | Micro cap | −74.90% | Nov 3, 2026 |
| KYNB | Kyntra Bio, Inc. | $32.82M | Micro cap | −22.66% | Nov 9, 2026 |
| MDNA.TO | Medicenna Therapeutics Corp. | $31.26M | Micro cap | −56.48% | Nov 12, 2026 |
| BYSI | BeyondSpring Inc. | $28.37M | Micro cap | −62.09% | Nov 12, 2026 |
| LTRN | Lantern Pharma Inc. | $27.87M | Micro cap | −46.17% | Nov 11, 2026 |
| CLRB | Cellectar Biosciences, Inc. | $24.01M | Micro cap | −47.30% | Nov 12, 2026 |
| BFRI | Biofrontera Inc. | $22.72M | Micro cap | +77.91% | Nov 11, 2026 |
| TPST | Tempest Therapeutics, Inc. | $17.86M | Micro cap | −89.96% | Nov 5, 2026 |
| LSTA | Lisata Therapeutics, Inc. | $15.68M | Micro cap | −30.40% | Nov 5, 2026 |
| PDSB | PDS Biotechnology Corporation | $12.49M | Micro cap | −82.56% | Nov 12, 2026 |
| BLRX | BioLineRx Ltd. | $11.79M | Micro cap | −26.63% | Aug 31, 2026 |
| LNAI | Lunai Bioworks Inc. | $9.97M | Micro cap | −89.34% | Sep 28, 2026 |
| BCAB | BioAtla, Inc. | $5.20M | Micro cap | −86.04% | Nov 12, 2026 |
| CRIS | Curis, Inc. | $3.86M | Micro cap | −5.52% | Nov 5, 2026 |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.